Wall Street brokerages expect that Guardant Health Inc (NASDAQ:GH) will report sales of $35.50 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Guardant Health’s earnings, with the lowest sales estimate coming in at $30.96 million and the highest estimate coming in at $38.45 million. The firm is scheduled to report its next quarterly earnings results on Thursday, August 8th.
According to Zacks, analysts expect that Guardant Health will report full year sales of $144.47 million for the current year, with estimates ranging from $132.40 million to $149.71 million. For the next year, analysts forecast that the firm will report sales of $212.99 million, with estimates ranging from $208.00 million to $216.56 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Guardant Health.
Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. The company had revenue of $36.66 million for the quarter, compared to the consensus estimate of $32.12 million.
Shares of NASDAQ GH traded down $4.46 during mid-day trading on Friday, reaching $85.05. 14,073 shares of the company were exchanged, compared to its average volume of 714,905. Guardant Health has a 52 week low of $27.04 and a 52 week high of $106.58. The stock has a market cap of $7.63 billion and a PE ratio of -30.38. The stock has a 50 day moving average of $85.06.
In other Guardant Health news, insider Richard B. Lanman sold 136,244 shares of the business’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $74.43, for a total value of $10,140,640.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Helmy Eltoukhy sold 90,000 shares of the business’s stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $65.28, for a total transaction of $5,875,200.00. The disclosure for this sale can be found here. Insiders sold 975,338 shares of company stock valued at $66,706,026 over the last three months.
A number of institutional investors have recently bought and sold shares of the business. Mascoma Wealth Management LLC bought a new position in shares of Guardant Health during the first quarter valued at about $54,000. Legal & General Group Plc bought a new position in shares of Guardant Health during the fourth quarter valued at about $85,000. Citigroup Inc. bought a new position in shares of Guardant Health during the fourth quarter valued at about $94,000. SG Americas Securities LLC bought a new position in shares of Guardant Health during the first quarter valued at about $108,000. Finally, Victory Capital Management Inc. bought a new position in shares of Guardant Health during the fourth quarter valued at about $124,000. 69.15% of the stock is owned by institutional investors and hedge funds.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Article: How is an ETF different from a mutual fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.